| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 7631- | Ins, | IP6, | Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate |
| - | Review, | Var, | NA |
| 7673- | iod, | Chemo, | Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study |
| - | Trial, | BC, | NA |
| 7672- | iod, | Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study |
| - | Trial, | BC, | NA |
| 7676- | iod, | Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR) |
| - | in-vivo, | BC, | NA |
| 7680- | iod, | doxoR, | Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection |
| - | vitro+vivo, | BC, | NA |
| 7684- | iod, | Molecular iodine impairs chemotherapy resistance and adverse effects in breast cancer treatments |
| - | Trial, | BC, | NA |
| 7687- | iod, | ESWT, | Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts |
| - | in-vivo, | BC, | MDA-MB-231 |
| 7654- | IP, | Dietary Supplementation of Inulin Contributes to the Prevention of Estrogen Receptor-Negative Mammary Cancer by Alteration of Gut Microbial Communities and Epigenetic Regulations |
| - | in-vivo, | BC, | NA |
| - | in-vivo, | BC, | NA |
| 7657- | IP, | Dietary inulin suppresses azoxymethane-induced aberrant crypt foci and colon tumors at the promotion stage in young Fisher 344 rats |
| - | in-vivo, | Var, | NA |
| 7662- | IP, | Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers |
| - | Trial, | Nor, | NA |
| 7666- | IP, | Short-chain fatty acid kinetics and concentrations are higher after inulin supplementation in young and older adults: a randomized trial |
| - | Trial, | Nor, | NA |
| 7668- | IP, | A phase 2 randomized, placebo-controlled trial of inulin for the prevention of gut pathogen colonization and infection among patients admitted to the intensive care unit for sepsis |
| - | Trial, | Sepsis, | NA |
| 7714- | IP6, | ACNs, | Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans |
| - | in-vivo, | Nor, | NA |
| 7721- | IP6, | Ins, | Effect of phytic acid and inositol on the proliferation and apoptosis of cells derived from colorectal carcinoma |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 7640- | IP6, | Ins, | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
| - | Trial, | BC, | NA |
| 7702- | IP6, | Ins, | capec, | Inositol Hexakisphosphate and Inositol Enhance the Inhibition of Colorectal Cancer Growth and Liver Metastasis by Capecitabine in a Mouse Model |
| - | in-vivo, | CRC, | NA |
| 7743- | ISL, | Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration |
| - | in-vivo, | Nor, | NA |
| 7753- | ISL, | LE, | Pharmacokinetic Interactions of a Licorice Dietary Supplement with Cytochrome P450 Enzymes in Female Participants |
| - | in-vivo, | Nor, | NA |
| 7748- | ISL, | GEM, | Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis |
| - | NA, | Lung, | NA |
| 7785- | ISL, | Enhancement of Oral Bioavailability and Anti-hyperuricemic Activity of Isoliquiritigenin via Self-Microemulsifying Drug Delivery System |
| - | in-vivo, | Nor, | NA |
| 7741- | isoFl, | Lyco, | SIL, | Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement |
| - | Trial, | Pca, | NA |
| 7740- | isoFl, | Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial |
| - | Trial, | Pca, | NA |
| 7739- | isoFl, | Soy, red clover, and isoflavones and breast cancer: a systematic review |
| - | Review, | BC, | NA |
| 7738- | isoFl, | Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced pro-inflammatory cytokines and immune suppressive cells |
| - | Trial, | Pca, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7885- | isoO, | Isoorientin from Gypsophila elegans induces apoptosis in liver cancer cells via mitochondrial-mediated pathway |
| 7822- | isoO, | Isoorientin Affects Markers of Alzheimer's Disease via Effects on the Oral and Gut Microbiota in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 7850- | ISQ, | Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study |
| - | Trial, | Nor, | NA |
| - | in-vivo, | Nor, | NA |
| 7791- | ISQ, | Isoquercitrin: pharmacology, toxicology, and metabolism |
| - | Review, | Nor, | NA |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7844- | ISQ, | Isoquercetin upregulates antioxidant genes, suppresses inflammatory cytokines and regulates AMPK pathway in streptozotocin-induced diabetic rats |
| - | NA, | Diabetic, | NA |
| 7841- | ISQ, | Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease |
| - | Human, | CardioV, | NA |
| 7837- | ISQ, | Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation |
| - | in-vivo, | Nor, | NA |
| 7559- | ISQ, | Difference in absorption of the two structurally similar flavonoid glycosides, hyperoside and isoquercitrin, in rats |
| - | in-vivo, | Nor, | NA |
| 7991- | itraC, | A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma |
| - | Trial, | BCC, | NA |
| 7990- | itraC, | A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial |
| - | Trial, | Ovarian, | NA |
| 7989- | itraC, | Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer |
| - | Trial, | NSCLC, | NA |
| 7987- | itraC, | Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer |
| - | Trial, | Pca, | NA |
| 8013- | itraC, | High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer |
| - | Case Report, | Pca, | NA |
| 7986- | itraC, | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma |
| - | Trial, | BCC, | NA |
| 8015- | itraC, | Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth |
| - | vitro+vivo, | BCC, | NA |
| 8016- | itraC, | Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma |
| - | Human, | Ovarian, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| - | in-vitro, | Lung, | A549 |
| 8047- | IVM, | The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug |
| - | Review, | Var, | NA |
| 8042- | IVM, | Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug |
| - | vitro+vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid